Biogen’s Q3 Aduhelm Sales Even Worse Than Expected

Executives Emphasize Low Expectations Through Year-End

 
• By Mandy Jackson
  
Success in business concept. Rising arrow and financial report.
Biogen's overall Q3 sales beat consensus, but expectations for Aduhelm are high • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip